After several exuberant years in the European M&A markets; the party seems to be ending. Following a disappointing end to 2018, the worst half-yearly figure in five years, there’s some worry that dealmaking may continue to plummet.
The European Commission (EC) is reviewing AbbVie’s [NYSE:ABBV] proposed acquisition of Botox producer Allergan [NYSE:AGN]. The merging parties have already pledged to divest such products as brazikumab, a drug under development for ulcerative colitis and Crohn’s disease, and Zenpep (pancrelipase), which treats a pancreatic disorder, but the EC may want more changes if it is to approve the deal. Dealreporter’s Pablo Mayo Cerqueiro and Mergermarket’s Mintoi Chessa-Florea joined us to discuss how the EC’s review is likely to go.
European IPO markets rebounded in the second quarter from a dismal start to the year. The region saw 45 IPOs with a combined offering size of €12.69bn during the second quarter of 2019. Here are 5 trends that emerged during H1 2019.
Here are 5 reasons why CEE M&A has remained broadly in line with 2018’s figures amid global concerns.
Saudi Arabia saw a significant increase in the volume and value of deals during the first half of 2019.
During the first half of 2019, Benelux M&A totalled €16.9bn, down 27.6% from the previous year. Deal count declined to 349 from 397. We review the 5 trends set to define the next 6 months of dealmaking in Benelux.
The DACH region saw a softer start to the year, experiencing a dip in deal making, yet still outpacing a subdued M&A market across Europe, according to Mergermarket's 1H19 DACH Trend Summary.
Norway sees strong inbound interest throughout a period of two halves while Danish market outlook remains optimistic despite declining activity in 1H19
M&A numbers decline due to plummeting Swedish figures, Denmark remains robust, Norway and Finland report growth
Activist investors are increasingly likely to put pressure on closely-knit “country club boards” in UK companies, two activist investors told the audience at the Mergermarket Corporate Development Summit in London this week.
German media conglomerate Axel Springer [ETR:SPR] has caught the eye of KKR [NYSE:KKR]. With Axel Springer’s founding family supporting its bid, KKR has an easier route towards taking the target off the market. Activistmonitor editor William Mace and Mergermarket’s resident DACH expert Emma-Victoria Farr joined us to discuss what the deal could mean for Axel Springer’s future.
No more items to load
Load more
